UK’s NICE Recommend Replacing Mantoux With TB Blood Tests For Key Patient Groups
Oxford, UK, 24 March 2011
The National Institute for Health and Clinical Excellence (NICE) released new clinical guidelines for the use of innovative TB blood tests called interferon-gamma release assays (IGRAs) for diagnosing latent tuberculosis infection (LTBI) on 24th March 2011.
Previous guidelines for diagnosis of LTBI released by NICE in 2006 recommended the use of a two step approach, starting with the Mantoux skin test and then only using IGRAs to confirm positive results.
In recognition of the mounting clinical evidence in favour of IGRA technology, the new guidelines recommend going straight to an IGRA test in a number of specified indications including:
In an outbreak situation when large numbers of individuals may need to be screened
Recent arrivals from high incidence countries who are from 16 to 34 years old
The immunocompromised and some HIV subjects
New NHS employees who have recently arrived from high incidence countries or who have had contact with patients in a setting where TB is highly prevalent
Hard to reach populations
In addition, the new guidelines recommend that an IGRA test be considered for initial use in individuals for whom Mantoux testing may be less reliable, such as those who have been BCG vaccinated, and for use in individuals whose Mantoux test result is positive.
These interventions are designed to identify subjects with LTBI so that they can be treated before they convert to active disease. This proactive approach will help to reduce the rates of active TB disease in the UK which have been rising over the past decade.
Until recently, the only test available to identify LTBI has been the Mantoux skin test which has been used for over 100 years and suffers from a variety of problems such as a high false negative rate amongst the immunocompromised and a high false positive rate amongst those who have been BCG vaccinated. The new IGRA tests recommended in these guidelines have been designed to overcome the deficiencies of the Mantoux test.
Oxford Immunotec Chief Executive, Peter Wrighton-Smith commented:
“I very much welcome the new guidelines from NICE which recognise the superior accuracy and convenience of IGRA testing in many populations. I am optimistic that the adoption of these guidelines will help to reverse the steadily increasing rates of TB seen in the UK over the past decade.”
이 사이트는 쿠키를 사용하여 귀하의 컴퓨터에 정보를 저장합니다. 본 사이트를 작동시키기 위해 필수 쿠키가 사용되며, 사용자 경험을 개선하기 위해서는 비-필수 쿠키가 사용됩니다. 쿠키 활성화 / 비활성화동의하기더 알아보기
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.